Downregulated microRNA-148b in circulating PBMCs in chronic myeloid leukemia patients with undetectable minimal residual disease: a possible biomarker to discontinue imatinib safely

BACKGROUND: A subset of patients with chronic myeloid leukemia (CML) can sustain a complete molecular response after discontinuing imatinib mesylate (IM). We focused on microRNAs (miRNAs), with the aim of finding a molecular biomarker to discriminate which patients can safely and successfully discon...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: Ohyashiki, Junko H, Ohtsuki, Kazushige, Mizoguchi, Izuru, Yoshimoto, Takayuki, Katagiri, Seiichiro, Umezu, Tomohiro, Ohyashiki, Kazuma
Format: Artigo
Jezik:Inglês
Izdano: Dove Medical Press 2014
Teme:
Original Research
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC4149385/
https://ncbi.nlm.nih.gov/pubmed/25187697
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DDDT.S66812
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki